IL17A and hepatocellular carcinoma: A formal interaction test confirmed that the detrimental effect of high IL-17A was amplified in the presence of hyperbilirubinemia (HR = 2.72, 95% CI 1.28-5.75, P = 0.009).<h4>Conclusion</h4>PD-1 inhibitor combined with targeted therapy is safe and feasible in advanced HCC patients with hyperbilirubinemia, although efficacy is inferior to that in patients with normal bilirubin.